



Hawaii MS and Neuroimmunology Center & Hawaii Infusion Center selected for OAK (ABP 692- Biosimilar Candidate to Ocrelizumab) Study.

A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP692, and Ocrevus (Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis. ABP 692 is a recombinant humanized glycosylated immunoglobulin isotype class G subclass 1 (IgG1) monoclonal antibody directed against CD20-expressing B-cells.



According to [Amgen Website](#), In the U.S., the cumulative reduction in drug spend for classes with biosimilar competition is estimated to have been \$21 billion over the past 6 years. The next few years will likely see several advancements, including expansion of biosimilars into pharmacy benefit reimbursement and biosimilars entering more classes, as well as additional approvals and launches of interchangeable biosimilars in the U.S.

Growth seems to be on the horizon for the marketplace with biosimilars, both in terms of breadth and depth. As of Q2 2022, the FDA lists 96 proposed biosimilar products enrolled in the FDA's Biosimilar Development Program, an increase of more than 70% since October 2015.8

Over the next few years, the growing number of biosimilars will likely lead to an evolution in the U.S. marketplace with biosimilars. These changes are likely to cement the role of biosimilars as viable and integral U.S. treatment options. Biosimilars will find new audiences in different prescriber specialties, pharmacists, payers, and patients. These developments may change the patient support program landscape, interactions at the pharmacy counter, and product-administration devices.



Our Hawaii patients, caregivers, families, neurologists & researchers are honored to contribute to the development of Neuroscience Biosimilars Therapy” [Natalia Gonzalez, MD](#), Director of [Hawaii MS and Neuroimmunology Center](#) & [Hawaii Infusion Center](#) and Sub investigator [MS Research Unit](#), who is fellowship trained in MS and Neuroimmunology and [Kore Kai Liow, MD](#), Neurologist & Principal

*Investigator, [MS Research Unit](#) Clinical Professor of Medicine (Neurology), Graduate Faculty, Clinical & Translational Research, University of Hawai'i John Burns School of Medicine. **Dedicated MS Research Hotline (808) 564-6141***



CLINICAL TRIALS